Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Barbanti P, Aurilia C, Filippi M, Doretti A, d'Onofrio F, Scatena P, Vecchio R, Messina R, Vinciguerra L, Ranieri A, Baldisseri F, Torelli P, Russo M, Cutrona C, Viticchi G, Egeo G, Autunno M, Pistoia F, Finocchi C, Camarda C, Messina S, Rinalduzzi S, Drago V, Caputi L, Bandettini di Poggio M, Quintana S, Salerno A, Bartolini M, Fiorentini G, Spieckert de Souza J, Di Stani F, Bonassi S, Porreca A, Italian Migraine Registry Study Group

Open source

DOI: 10.1007/s40120-026-00971-7
Published: 2026 Jun 9
Container: Neurology and therapy
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40120-026-00971-7,
  title = {Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.},
  author = {Barbanti P and Aurilia C and Filippi M and Doretti A and d'Onofrio F and Scatena P and Vecchio R and Messina R and Vinciguerra L and Ranieri A and Baldisseri F and Torelli P and Russo M and Cutrona C and Viticchi G and Egeo G and Autunno M and Pistoia F and Finocchi C and Camarda C and Messina S and Rinalduzzi S and Drago V and Caputi L and Bandettini di Poggio M and Quintana S and Salerno A and Bartolini M and Fiorentini G and Spieckert de Souza J and Di Stani F and Bonassi S and Porreca A and Italian Migraine Registry Study Group},
  year = {2026},
  journal = {Neurology and therapy},
  doi = {10.1007/s40120-026-00971-7},
  url = {https://doi.org/10.1007/s40120-026-00971-7}
}

RIS

TY  - JOUR
TI  - Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.
AU  - Barbanti P
AU  - Aurilia C
AU  - Filippi M
AU  - Doretti A
AU  - d'Onofrio F
AU  - Scatena P
AU  - Vecchio R
AU  - Messina R
AU  - Vinciguerra L
AU  - Ranieri A
AU  - Baldisseri F
AU  - Torelli P
AU  - Russo M
AU  - Cutrona C
AU  - Viticchi G
AU  - Egeo G
AU  - Autunno M
AU  - Pistoia F
AU  - Finocchi C
AU  - Camarda C
AU  - Messina S
AU  - Rinalduzzi S
AU  - Drago V
AU  - Caputi L
AU  - Bandettini di Poggio M
AU  - Quintana S
AU  - Salerno A
AU  - Bartolini M
AU  - Fiorentini G
AU  - Spieckert de Souza J
AU  - Di Stani F
AU  - Bonassi S
AU  - Porreca A
AU  - Italian Migraine Registry Study Group
PY  - 2026
JO  - Neurology and therapy
DO  - 10.1007/s40120-026-00971-7
UR  - https://doi.org/10.1007/s40120-026-00971-7
ER  -

APA

P, B., C, A., M, F., A, D., F, D., P, S., R, V., R, M., L, V., A, R., F, B., P, T., M, R., C, C., G, V., G, E., M, A., F, P., C, F., C, C., S, M., S, R., V, D., L, C., M, B. D. P., S, Q., A, S., M, B., G, F., J, S. D. S., F, D. S., S, B., A, P., & Group, I. M. R. S. (2026). Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.. Neurology and therapy. https://doi.org/10.1007/s40120-026-00971-7

Source records

pubmed · retrieved 2026-09-25T01:58:27.059Z